anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the subject composition, containing a specific quaternary ammonium salt type compound and a silicone derivative, having low irritancy to the skin and hair, excellent in high foaming properties, high washing properties and resistance to hard water and simultaneously capable of exhibiting excellent conditioning effects. CONSTITUTION:A shampoo composition containing a quaternary ammonium salt type compound having secondary or tertiary amino group and quaternary ammonium group in an aliphatic chain or an ether, an ester or an acyl compound having the aliphatic chain {preferably a compound expressed by formula I [R<1> is alkyl or alkenyl; R<2> to R<4> are alkyl or hydroxyalkyl; M is CONG (G is H, alkyl or hydroxyalkyl), O or COO; Y is H, alkyl, etc.; X is H or OH; A is halogen, etc.; m is 2 or 3; n is 0-5] (e.g. a compound expressed by formula II) and a silicone derivative (e.g. dimethylpolysiloxane). The composition is capable of imparting touch such as flexibility and smoothness and excellent combing properties to hair after washing.
The present invention relates to a new method for prevention and treatment of type 2 diabetes based on administration of inhibitors of phosphodiesterase 10A (PDE l0A) expression or PDEl0A activity in combination with agents that enhance or mimic GLP-1 signalling in the beta cell, long-acting GLP-1 analogs like exendin-4 or inhibitors of GLP-1 breakdown (DPP-­IV inhibitors). The invention is based upon the original findings that the cAMP­phosphodiesterase (PDE) isoform 10A, an enzyme that degrades cAMP with high affinity and that so far was mainly associated with brain function is not only expressed in brain but also in endocrine cells like pancreatic islets of Langerhans, the site of insulin secretion, as well as in pancreatic beta cell lines (MIN6 and INS 1). This expression was detected both at the Mrna level (real-time quantitative RT-PCR or microarray analysis), and protein as evidenced by Western blots with an affinity-purified rabbit polyclonal antibody. The high abundance of PDEl0A in neuro-endocrine cell types (brain, adrenal gland, pituitary, islets of Langerhans) which demonstrates a clear role for PDElOA in hormone secretion. Furthermore it was found that PDElOA is induced by food intake in mouse islets and severely (70%) lowered by overnight fasting. As PDE l0A was specifically down-regulated (mRNA-level) in genetically modified mice that do not express functional GLP-1 or GIP receptors in beta cells (DIRKO mice), we claim in~retin receptors induce the mRNA in beta cells. This was further demonstrated in INS1 cells, where PDEl0A is induced by 6-24 exposure to agents that raise cAMP in the cells, such as forskolin, IBMX and GLP-l. Based on these observation a combination medicament has been developed combining the PDEl0A inhibitor, Dipyridamole or derivatives thereof or the PDE10 inhibitor, papaverine, to remarka~ y enhance the effect of agents that enhance or mimic GLP-1 signalling in the beta cell, Long­acting GLP-1 analogs like exendin-4 or inhibitors of GLP-1 breakdown (DPP-IV inhibitors) to treat a disorder of impaired insulin secretion such as type 2 diabetes, maturity-onset diabetes of the young (MODY), latent autoimmune diabetes adult (LADA), impaired glucose tolerance (MT), impaired fasting glucose (IFG), gestational diabetes, and metabolic syndrome X and more particularly type 2 diabetes.
Cohort 2 - Group BA will receive placebo (Sterile Saline Solution 0.9%) at study weeks 0, 4, and 8. Then, Group BA will receive allogeneic HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) at weeks 20, 24, and 28 after a washout period of 12 weeks between placebo and active treatment.
Consenting patients will be randomly allocated using a random number table to BpTRU in an exam room. The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
There are no published longitudinal studies examining the impact of traumatic events on risk behavior among HIV-positive men and women. As a result, we know very little about how stress, particularly trauma-related stress, influences HIV risk behavior. This study will be one of the first randomized studies to examine the efficacy of reducing HIV risk behavior by combining a trauma-focused stress reduction intervention with a standard HIV prevention skills intervention. This study is specifically targeting a low-income, urban population, a group that experiences a disproportionate rate of crime as well as HIV infection. Findings of the research will likely provide information on the relationship between trauma and risk behavior. Furthermore, this research can identify key issues related to stress, psychosocial factors, and overall health that will be relevant to investigate in future, larger-scale studies of HIV-positive as well as HIV-negative populations.

Individuals who reported living with HIV, engaging in HIV risk behavior in the past 3 months, experiencing a traumatic stressor and trauma-related symptoms in the past 3 months were assigned to one of three conditions: 1) standard HIV prevention skills; 2) standard HIV prevention skills + trauma-focused stress reduction skills training; or 3) trauma-focused stress reduction skills training.
BACKGROUND: Cerebral ischemia-reperfusion injury (CIRI) is a destructive adverse reaction of ischemic stroke, leading to high disability and mortality rates. Salvia miltiorrhiza Bge. (Danshen, DS) processed with porcine cardiac blood (PCB-DS), a characteristic processed product, has promising anti-ischemic effects. However, the underlying mechanism of PCB-DS against CIRI remains unclear.
PURPOSE: Ferroptosis is demonstrated to be involved in CIRI. The aim of this study was to explore the molecular mechanism underlying PCB-DS inhibited GLRX5-mediated ferroptosis alleviating CIRI, which was different from DS.
METHODS: Quality evaluation of PCB-DS and DS was conducted by UPLC. Pharmacological activities of PCB-DS and DS against CIRI were compared using neurobehavioral scores, infarct volume, proinflammatory factors, and pathological examinations. Proteomics was employed to explore the potential specific mechanism of PCB-DS against CIRI, which was different from DS. Based on the differential protein GLRX5, ferroptosis-related iron, GSH, MDA, SOD, ROS, liperfluo, and mitochondrial morphology were analyzed. Then, the proteins of GLRX5-mediated iron-starvation response and SLC7A11/GPX4 were analyzed. Finally, OGD/R-induced SH-SY5Y cells upon GLRX5 silencing were constructed to demonstrate that PCB-DS improved CIRI by GLRX5-mediated ferroptosis.
RESULTS: PCB-DS better alleviated CIRI through decreasing neurological score, reducing the infarct volume, and suppressing the release of inflammatory cytokines than DS. Proteomics suggested that PCB-DS may ameliorate CIRI by inhibiting GLRX5-mediated ferroptosis, which was different from DS. PCB-DS reversed the abnormal mitochondrial morphology, iron, GSH, MDA, SOD, ROS, and liperfluo to inhibit ferroptosis in vitro and in vivo. PCB-DS directly activated GLRX5 suppressing the iron-starvation response and downregulated the SLC7A11/GPX4 signaling pathway to inhibit ferroptosis. Finally, silencing GLRX5 activated the iron-starvation response in SH-SY5Y cells and PCB-DS unimproved OGD/R injury upon GLRX5 silencing.
CONCLUSION: Different from DS, PCB-DS suppressed ferroptosis to alleviate CIRI through inhibiting GLRX5-mediated iron-starvation response. These findings give a comprehensive understanding of the molecular mechanism underlying the effect of PCB-DS against CIRI and provide evidence to assess the product in clinical studies.
PURPOSE: To evaluate the clinical and aesthetic outcome of percutaneous injection of sclerosant agents to treat head and neck cystic malformations (HNCM) and to assess their recurrence rate based on histology and site.
METHODS: Fifty-four subjects (mean age 46 years) with HNCM treated by percutaneous injection of sclerosant agents between January and December 2017 were included. Imaging and clinical data before and after the procedure were collected. Quality of Life Index, Pain Visual Analogue Scale, and Aesthetic Scale scores were measured to assess clinical and aesthetic outcomes. A size reduction of ≥ 70% assessed through the visual scale was considered significant.
RESULTS: Of the 54 HNCM, there were 26 (48%) lymphatic malformations (LM), 13 (24%) salivary epithelial duct cysts of the parotid gland, 12 (22%) salivary mucoceles, and 3 (5%) branchial cysts. A significant size reduction and a satisfactory clinical-aesthetic outcome were observed in all types of LM. The number of reinterventions was significantly associated with the number of lesions (p < 0.001). The lowest number of interventions was observed in macrocystic lymphatic malformations (average of 1.2 interventions). All salivary epithelial duct cysts showed a significant reduction in size, a satisfactory clinical-aesthetic outcome, and an average of 1.16 interventions per patient. Mucoceles had a worse response, with only 3/14 patients showing a satisfactory and long-lasting clinical outcome (average of 1.16 interventions). Treatment of branchial cysts showed the worst outcome with a limited clinical response (3/3).
CONCLUSION: Percutaneous injection of sclerosant agents may be considered as a first-line treatment for LM and salivary epithelial duct cysts.
FIELD: medicine.SUBSTANCE: invention relates to traumatology and orthopaedics, and can be used for treating osteoarthrosis of knee joint. Introduced into an affected joint through a lower-lateral penetration needle 20G (0.9 × 70 mm) into the external cavity of knee joint of 4.5 ml suspension of stromal-vascular fraction of cell product in Hartman's solution. A cellular product is represented by a suspension of stromal-vascular fraction cells prepared by enzymatic treatment of adipose tissue in volume of 100–300 ml, taken by syringe tumescent liposuction. Enzymatic treatment of washed fatty tissue in Hartmann solution is carried out with 0.15 % collagenase of type 2. Further incubation is carried out on shaker for 30 minutes at temperature of 37 °C. Mixture is filtered through a sieve with pore diameter of 70–100 mcm. It is followed by washing in Hartmann's solution 3 times. It is centrifuged for 7 minutes at 300 g.EFFECT: method provides higher stable therapeutic effect due to introduction of regenerative cells participating in cartilage tissue repair within one surgical procedure.1 cl, 2 ex
PURPOSE:The titled pharmaceutical for oral use, containing porphyrin or a salt thereof as an active ingredient and capable of preventing the occurrence, growth,, metastasis and recurrence of malignant tumor. CONSTITUTION:A pharmaceutical containing prophyrin or a salt thereof. The prophyrinis a generic name of porphyrin derivatives and examples thereof include etiporphyrin, mesoporphyrin, protoporphyrin, deuteroporphyrin, hematoporphyrin, coproporphyrin, uroporphyrin, etc. The administration thereof in a small daily dose, e.g. up to about 60mg, is found to be capable of remark ably suppressing or inhibiting the growth of tumor in the object. The porphyrin or salt thereof in a small daily dose is capable of normally holding the character of cells and adjustment of function or promoting the normalization thereof, preventing the occurrence or malignant tumor, e.g. cancer, or suppressing the growth, metastasis and recurrence thereof.
This disclosure describes frameworks and techniques directed to incorporating user input into the analysis and verification of models extracted from a database. The database can include an online database, such as clinicaltrials.gov administered by the United States National Institutes of Health. This disclosure describes implementations that utilize models derived from clinical study data extracted from a database and analyzes the models. The analysis of the models can be used to verify the results of the clinical studies from which the models were derived. Additionally, the analysis of the models can identify a combination of models that can be used to predict health outcomes of one or more biological conditions for one or more populations. User input can be utilized during the validation and optimization processes to improve the accuracy of the model output.
Central nervous system (CNS)-resident cells such as microglia, oligodendrocytes and astrocytes are gaining increasing attention in respect to their contribution to CNS pathologies including multiple sclerosis (MS). Several studies have demonstrated the involvement of pro-inflammatory glial subsets in the pathogenesis and propagation of inflammatory events in MS and its animal models. However, it has only recently become clear that the underlying heterogeneity of astrocytes and microglia can not only drive inflammation, but also lead to its resolution through direct and indirect mechanisms. Failure of these tissue-protective mechanisms may potentiate disease and increase the risk of conversion to progressive stages of MS, for which currently available therapies are limited. Using proteomic analyses of cerebrospinal fluid specimens from patients with MS in combination with experimental studies, we here identify Heparin-binding EGF-like growth factor (HB-EGF) as a central mediator of tissue-protective and anti-inflammatory effects important for the recovery from acute inflammatory lesions in CNS autoimmunity. Hypoxic conditions drive the rapid upregulation of HB-EGF by astrocytes during early CNS inflammation, while pro-inflammatory conditions suppress trophic HB-EGF signaling through epigenetic modifications. Finally, we demonstrate both anti-inflammatory and tissue-protective effects of HB-EGF in a broad variety of cell types in vitro and use intranasal administration of HB-EGF in acute and post-acute stages of autoimmune neuroinflammation to attenuate disease in a preclinical mouse model of MS. Altogether, we identify astrocyte-derived HB-EGF and its epigenetic regulation as a modulator of autoimmune CNS inflammation and potential therapeutic target in MS.
PURPOSE: To obtain a composition for suppressing or preventing the skin irritation due to a percutaneous medicinal transport system or the skin irritation or sensitization due to a sensitizing ingredient, or affording anti-inflammatory effect. CONSTITUTION: This composition comprises a mast cell degranulator capable of inducing immunologically tolerant condition to a skin-sensitizing medicine or substance to be transported before or at the beginning of percutaneous medicinal transport. It is preferable that such a degranulator, pref. cis-urocanic acid or its analogue or metabolite is penetrable through the epidermis and percutaneously administrable. Administration of the mast cell degranulator before, during or after each percutaneous medicinal transport affords countersensitization of immune resistance. Alternatively, the countersensitization can be induced by use of the mast cell degranulator.
BACKGROUND AND OBJECTIVES: Prevertebral soft-tissue swelling (PSTS) after anterior cervical diskectomy and fusion (ACDF) is known to be influenced by several factors. We considered the effect of lateral deviation on the traction force and attempted to find a relationship with the PSTS. This study was designed to evaluate the preoperative lateral deviation of the hyoid bone and thyroid cartilage and its effect on PSTS, airway collapse, and clinical outcomes after ACDF.
METHODS: Preoperative lateral deviations of the hyoid bone and thyroid cartilage at the superior cornu and inferior cornu were measured. To assess the effect of lateral deviation, patients who underwent 1 or 2 level ACDF with the left-sided approach were divided into a deviation group (left-sided deviation >5 mm or >10 mm) and a nondeviation group (left-sided deviation <5 mm or <10 mm). Difference of preoperative and postoperative PSTS (dPSTS), airway collapse, dysphagia score, and Neck Disability Index were compared between the 2 groups.
RESULTS: Lateral deviation was measured in 290 patients, and 145 were enrolled to assess the effect of lateral deviation. Left-sided deviation was more common than right-sided deviation in all 3 structures (the hyoid bone, superior cornu, and inferior cornu of the thyroid cartilage). The deviation group demonstrated a significantly larger dPSTS at the C3 and C4 levels, more airway collapse at the C4 level, and a higher dysphagia score. There was no significant difference in the Neck Disability Index between the 2 groups. Lateral deviation significantly correlated with dPSTS (C3, C4, C5, and C6 levels) and airway collapse (C3 and C4 levels).
CONCLUSION: A left-sided deviation of more than 5 mm of the hyoid bone or thyroid cartilage discouraged the left-sided approach for ACDF because of the aggravation of dPSTS, airway collapse, and dysphagia postoperatively.
The relationship between gut microbiota and obesity has recently been an important subject for research as the gut microbiota is thought to affect body homeostasis including body weight and composition, intervening with pro and prebiotics is an intelligent possible way for obesity management. To evaluate the effect of hypo caloric adequate fiber regimen with probiotic supplementation and physical exercise, whether it will have a good impact on health, body composition, and physique among obese Egyptian women or has no significant effect. The enrolled 58 women, in this longitudinal follow-up intervention study; followed a weight loss eating regimen (prebiotic), including a low-carbohydrate adequate-fiber adequate-protein dietary pattern with decreased energy intake. They additionally received daily probiotic supplements in the form of yogurt and were instructed to exercise regularly for 3 months. Anthropometric measurements, body composition, laboratory investigations, and microbiota analysis were obtained before and after the 3 months weight loss program. Statistically highly significant differences in the anthropometry, body composition parameters: and obesity-related biomarkers (Leptin, ALT, and AST) between the pre and post-follow-up measurements at the end of the study as they were all decreased. The prebiotic and probiotic supplementation induced statistically highly significant alterations in the composition of the gut microbiota with increased relative abundance of Lactobacillus, Bifidobacteria, and Bacteroidetes and decreased relative abundance of Firmicutes and Firmicutes/Bacteroidetes Ratio. Hypo caloric adequate fiber regimen diet with probiotics positively impacts body composition and is effective for weight loss normalizing serum Leptin and AST.
The invention discloses axial ALA-modified silicon phthalocyanine and a preparation method and an application thereof, and belongs to the field of photodynamic drug or photosensitizer preparation. The silicon phthalocyanine provided by the invention can be used in photodynamic treatment, photodynamic diagnosis or photodynamic disinfection as a photosensitizer. The silicon phthalocyanine has a structure containing a second-generation photosensitizer ALA. Cells can release two photosensitizers, namely ALA and silicon phthalocyanine. Photodynamic therapy window is expanded. The silicon phthalocyanine provided by the invention shows a good synergistic anticancer effect and a high photodynamic activity.
FIELD: medical engineering. SUBSTANCE: method involves pressing and polymerizing siloxane composition containing siloxane rubber, filler, polymerization initiator and pigments. The preliminary siloxane composition is treated with ultrahigh frequency radiation by applying ultrahigh frequency field of 700-900 W for 1 min. The gingival prosthesis has the second layer of acryl base material. Both layers are polymerized by applying ultrahigh frequency field of 700-900 W for 3-5 min. The siloxane composition and acryl base material are to be taken in 2-3:1 proportion. EFFECT: enhanced effectiveness of treatment. 3 cl
Traditionally, heart murmurs are diagnosed through cardiac auscultation, which requires specialized training and experience. The purpose of this study is to predict patients' clinical outcomes (normal or abnormal) and identify the presence or absence of heart murmurs using phonocardiograms (PCGs) obtained at different auscultation points. A semi-supervised model tailored to PCG classification is introduced in this study, with the goal of improving performance using time-frequency deep features. The study begins by investigating the behavior of PCGs in the time-frequency domain, utilizing the Stockwell transform to convert the PCG signal into two-dimensional time-frequency maps (TFMs). A deep network named AlexNet is then used to derive deep feature sets from these TFMs. In feature reduction, redundancy is eliminated and the number of deep features is reduced to streamline the feature set. The effectiveness of the extracted features is evaluated using three different classifiers using the CinC/Physionet challenge 2022 dataset. For Task I, which focuses on heart murmur detection, the proposed approach achieved an average accuracy of 93%, sensitivity of 91%, and F1-score of 91%. According to Task II of the CinC/Physionet challenge 2022, the approach showed a clinical outcome cost of 5290, exceeding the benchmark set by leading methods in the challenge.
In patients with treatment resistent hypertension renal nerve ablation emerged as an effective interventional approach of treating hypertensive disease with a progressively increasing fall in blood pressure. Decreased activity of the sympathetic nervous system is one of the major underlying pathogenetic mechanism of the fall in blood pressure but the precise mechanisms that causes the fall in blood pressure in the short-term and, in particular, long-term remains elusive. The objective of the study is to understand the pathogenetic mechanisms of renal denervation beyond the reduced activity of the sympathetic nervous system. In 100 hypertensive patients most advanced technology will be applied, before and repeatedly after renal denervation, throughout the follow-up period of 1 year. Systemic activity of the renin angiotensin aldosterone system, renal perfusion (by MRI spin labelling technique), local activity of the renin angiotensin system in the kidney (urinary angiotensinogen concentrations), sodium excretion and total sodium content (23 Na-MRI technique) and vascular remodelling of small (retinal arterioles 50 - 150 µm) and large arteries (carotid - femoral pulse wave velocity and augmentation index, both measured over 24 hours) will be assessed. Identification of the pathogenetic mechanisms involved in the fall in blood pressure after renal denervation may help to identify those hypertensive patients that profit most from renal nerve ablation in terms of blood pressure reduction.
PURPOSE:To not only keep health but also prevent various intractable diseases by adding a favorite beverage to urine, drinking the resultant urine, returning the urine into the body and enhancing resistance of the body. CONSTITUTION:Urine is united with a favorite beverage such as beer, whisky or wine or a concentrated extract thereof in an amount so as not to disturb effects of the urine. Thereby, a functional beverage is prepared. The resultant beverage is then drunk to return the urine into the body. As a result, various nutriments of the urine including ingredients unique to the urine and uric acid are united to perform action. Thereby, health can be kept and intractable diseases can be prevented.